Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 1
1916 1
1917 1
1919 1
1920 1
1921 1
1928 1
1931 1
1937 1
1939 1
1940 1
1941 1
1942 2
1943 1
1944 1
1945 1
1946 4
1947 1
1948 3
1949 9
1950 12
1951 8
1952 13
1953 25
1954 19
1955 22
1956 25
1957 41
1958 28
1959 27
1960 28
1961 36
1962 52
1963 55
1964 98
1965 88
1966 243
1967 355
1968 529
1969 566
1970 639
1971 785
1972 881
1973 942
1974 1189
1975 1226
1976 1318
1977 1388
1978 1500
1979 1665
1980 1947
1981 1972
1982 2086
1983 2386
1984 2510
1985 2810
1986 2784
1987 2925
1988 2985
1989 3777
1990 3925
1991 4255
1992 4512
1993 4822
1994 5305
1995 5977
1996 6671
1997 6996
1998 7309
1999 7417
2000 7905
2001 8290
2002 8842
2003 9590
2004 10096
2005 11519
2006 12299
2007 12923
2008 13995
2009 15337
2010 16713
2011 18758
2012 20275
2013 21798
2014 24725
2015 26380
2016 27790
2017 29620
2018 31086
2019 33544
2020 38252
2021 42250
2022 44285
2023 42174
2024 15208

Text availability

Article attribute

Article type

Publication date

Search Results

579,010 results

Results by year

Filters applied: . Clear all
Page 1
Autosomal dominant polycystic kidney disease.
Torres VE, Harris PC, Pirson Y. Torres VE, et al. Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1. Lancet. 2007. PMID: 17434405 Review.
Autosomal dominant polycystic kidney disease is the most prevalent, potentially lethal, monogenic disorder. ...An increased understanding of the disorder's underlying genetic, molecular, and cellular mechanisms and a better appreciation of its progress …
Autosomal dominant polycystic kidney disease is the most prevalent, potentially lethal, monogenic disorder. ...A …
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
Müller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, van Eerde A, Guirchoun P, Harris T, Hoorn EJ, Knoers NVAM, Korst U, Mekahli D, Le Meur Y, Nijenhuis T, Ong ACM, Sayer JA, Schaefer F, Servais A, Tesar V, Torra R, Walsh SB, Gansevoort RT. Müller RU, et al. Nephrol Dial Transplant. 2022 Apr 25;37(5):825-839. doi: 10.1093/ndt/gfab312. Nephrol Dial Transplant. 2022. PMID: 35134221 Free PMC article. Clinical Trial.
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in A …
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the man …
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, Schaefer F. Mekahli D, et al. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022. Clin J Am Soc Nephrol. 2023. PMID: 36719158 Free PMC article. Clinical Trial.
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD). ...CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety, Pharmacokineti …
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal d …
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. ...CONCLUSIONS: Tolvaptan, as compared with placebo, slowed the increase in total ki …
BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hy …
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.
Nowak KL, Hopp K. Nowak KL, et al. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):577-584. doi: 10.2215/CJN.13291019. Epub 2020 Feb 21. Clin J Am Soc Nephrol. 2020. PMID: 32086281 Free PMC article. Review.
Autosomal dominant polycystic kidney disease is characterized by progressive development and enlargement of kidney cysts, leading to ESKD. ...Beyond single-intervention trials focused on metabolic reprograming in autosomal dominant …
Autosomal dominant polycystic kidney disease is characterized by progressive development and enlargement of k …
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
BACKGROUND: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, 60 ml per minute), the vasopressin V(2)-receptor antagonist tolvaptan slowed the growth in total …
BACKGROUND: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPK …
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.
Reiterová J, Tesař V. Reiterová J, et al. Int J Mol Sci. 2022 Mar 19;23(6):3317. doi: 10.3390/ijms23063317. Int J Mol Sci. 2022. PMID: 35328738 Free PMC article. Review.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, with an estimated prevalence between 1:1000 and 1:2500. ...Moreover, metabolic alterations in cystic cells including defective glucose metabolism, impaired b …
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, with an estimated …
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. Chebib FT, et al. J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18. J Am Soc Nephrol. 2018. PMID: 30228150 Free PMC article. Review.
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug tre …
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the manag …
Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT, Torres VE. Chebib FT, et al. Am J Kidney Dis. 2021 Aug;78(2):282-292. doi: 10.1053/j.ajkd.2020.12.020. Epub 2021 Mar 8. Am J Kidney Dis. 2021. PMID: 33705818 Review.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of kidney failure, accounting for 5%-10% of cases. ...Surrogate prognostic biomarkers are required to predict future decline in kidney function …
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of kidney fail …
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Torres VE, et al. Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043. Nephrol Dial Transplant. 2018. PMID: 28379536 Free PMC article. Clinical Trial.
BACKGROUND: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo. ...The safety profile on exposure to tolvaptan in TEMPO 4:4 was sim …
BACKGROUND: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimat …
579,010 results
You have reached the last available page of results. Please see the User Guide for more information.